862 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
3 Key Factors to Look Out for in Biogen's Q1 Results http://www.zacks.com/stock/news/257454/3-key-factors-to-look-out-for-in-biogens-q1-results?cid=CS-ZC-FT-257454 Apr 24, 2017 - With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.
Should Gilead Sciences Acquire NewLink Genetics? https://www.fool.com/investing/2017/04/21/gilead-sciences-should-acquire-newlink-genetics.aspx?source=iedfolrf0000001 Apr 21, 2017 - NewLink Genetics intriguing IDO-inhibitors could make it a target of Gilead Sciences.
10 Reasons Merck Could Be the World's Most Perfect Stock https://www.fool.com/investing/2017/04/21/10-reasons-merck-could-be-the-worlds-most-perfect.aspx?source=iedfolrf0000001 Apr 21, 2017 - Merck may be a picture-perfect stock for long-term investors to consider buying.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Oracle, Merck, Honeywell and Altria http://www.zacks.com/stock/news/257082/the-zacks-analyst-blog-highlights-berkshire-hathaway-oracle-merck-honeywell-and-altria?cid=CS-ZC-FT-257082 Apr 20, 2017 - The Zacks Analyst Blog Highlights: Berkshire Hathaway, Oracle, Merck, Honeywell and Altria
Top Research Reports for Today: BRK.B, ORCL, MRK http://www.zacks.com/research-daily/110697/top-research-reports-for-today-brkb-orcl-mrk?cid=CS-ZC-FT-110697 Apr 19, 2017 - Top Research Reports for Today: BRK.B, ORCL, MRK
Is J&J's Pharma Sales Slowdown a Warning for Other Players? http://www.zacks.com/stock/news/256931/is-jjs-pharma-sales-slowdown-a-warning-for-other-players?cid=CS-ZC-FT-256931 Apr 19, 2017 - Johnson & Johnson (JNJ) reported mixed first-quarter 2017 earnings results on Tuesday.
Better Buy: Merck & Co. Inc. vs. Johnson & Johnson https://www.fool.com/investing/2017/04/19/better-buy-merck-co-inc-vs-johnson-johnson.aspx?source=iedfolrf0000001 Apr 19, 2017 - Does Merck's sizzling-hot cancer drug Keytruda give it a leg up over longtime winner Johnson & Johnson?
Roche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion http://www.zacks.com/stock/news/256721/roches-rhhby-cancer-drug-gets-fda-nod-for-label-expansion?cid=CS-ZC-FT-256721 Apr 18, 2017 - Roche Holding AG's (RHHBY) unit, Genentech, announced that its drug Tecentriq (atezolizumab) has received FDA approval on an accelerated basis for initial treatment of people with advanced urothelial carcinoma (mUC).
J&J (JNJ) Q1 Earnings Beat Estimates, Pharma Sales Slow Down http://www.zacks.com/stock/news/256709/jj-jnj-q1-earnings-beat-estimates-pharma-sales-slow-down?cid=CS-ZC-FT-256709 Apr 18, 2017 - Johnson & Johnson (JNJ) reported mixed first quarter results, with earnings beating expectations while sales missing the same.
Zoetis (ZTS) Inks Agreement to Acquire Nexvet Biopharma http://www.zacks.com/stock/news/256527/zoetis-zts-inks-agreement-to-acquire-nexvet-biopharma?cid=CS-ZC-FT-256527 Apr 17, 2017 - Zoetis Inc. (ZTS) announced an agreement to buy Nexvet Biopharma plc (NVET) for an aggregate equity valuation of approximately $85 million

Pages: 1...7576777879808182838485...87

<<<Page 80>